Physician profile
Keyoor Patel
NPI 1598984668
$31,748.97
in general payments reported to CMS, 2019-2025
47 companies · $4,018 in 2025
The $4,018 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,430 · 2020: $1,807 · 2021: $3,151 · 2022: $4,255 · 2023: $6,245 · 2024: $5,842 · 2025: $4,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,310 · Consulting Fee: $1,575 · Travel and Lodging: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,931.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,310.00 |
| Consulting Fee | $1,575.00 |
| Travel and Lodging | $1,288.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $12,711.12 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Evoque |
| Abbott Laboratories | $5,338.67 | 2019-2025 | Triclip, Mitraclip, Navitor |
| Janssen Pharmaceuticals, INC | $3,520.71 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,493.68 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $1,144.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,006.02 | 2019-2025 | |
| Boston Scientific Corporation | $896.71 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Amgen INC. | $718.59 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $625.47 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Chiesi USA, INC. | $521.18 | 2019-2024 | Cleviprex, Kengreal |
| Medtronic, INC. | $518.37 | 2021-2025 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $418.44 | 2021-2025 | Verquvo, Capvaxive |
| Medtronic Vascular, INC. | $411.82 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $382.51 | 2019-2025 | Gore Cardioform Septal Occluder |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.25 | 2020-2024 | Jardiance |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keyoor Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.